Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
86 hedge funds and large institutions have $475M invested in Revance Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 19 reducing their positions, and 27 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 19
14% more call options, than puts
Call options by funds: $935K | Put options by funds: $822K
17% less funds holding
Funds holding: 104 → 86 (-18)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
49% less capital invested
Capital invested by funds: $929M → $475M (-$454M)
67% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$23M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$11.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$3.06M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.82M |
| 5 |
JCG
JHL Capital Group
Chicago,
Illinois
|
+$2.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$19M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$12.2M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$10.5M |
| 4 |
Renaissance Technologies
New York
|
-$7.38M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$4.42M |
RVNC Hedge Fund Activity: Q1 2016 in Review
86 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2016, worth a combined $475M — down 49% from $929M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of RVNC and 9 opened new positions — a net loss of 18 holders — while 19 trimmed existing stakes and 40 added.
The largest buyer was Wellington Management Group, adding an estimated $23M. The largest seller was Fidelity Investments, exiting entirely with an estimated $19M sold.
- 86 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2016, down from 104 in Q4 2015.
- Funds reported $475M of Revance Therapeutics, Inc. stock for Q1 2016, down 49% quarter-over-quarter.
- 9 funds opened new Revance Therapeutics, Inc. positions in Q1 2016 and 27 closed out, a net change of -18 holders.
- The largest Revance Therapeutics, Inc. buyer in Q1 2016 was Wellington Management Group, an estimated $23M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2016 was Fidelity Investments, an estimated $19M sold.
Based on aggregated 13F filings for Q1 2016.